Literature DB >> 11104826

Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells.

T W Moody1, R T Jensen, L Garcia, J Leyton.   

Abstract

The ability of nonpeptide antagonists to interact with neuromedin B receptors on C6 cells was investigated. 2-[3-(2, 6-Diisopropyl-phenyl)-ureido]3-(1H-indol-3-yl)-2-methyl-N-(1-pyridin- 2-yl-cyclohexylmethyl)-proprionate (PD165929), 3-(1H-indol-3-yl)-2-methyl-2-[3(4-nitro-phenyl)-ureido]-N-(1-pyridin- 2-yl-cyclohexylmethyl)-propionamide (PD168368) and 3-(1H-indol-3-yl)-N-[1-(5-methoxy-pyridin-2-yl)-cyclohexylmethyl]- 2-m ethyl-2-[3-(4-nitro-phenyl)-ureido]-propionamide (PD176252) inhibited (125I-Tyr0)neuromedin B binding with IC50 values of 2000, 40 and 50 nM, respectively. Because neuromedin B is a G-protein coupled serpentine receptor, the effects of neuromedin B antagonists on second messenger production and proliferation were investigated. PD168368 inhibited the ability of 10 nM neuromedin B to cause elevation of cytosolic Ca2+, whereas it had no effect on basal cytosolic Ca2+. PD168368 inhibited the ability of 100 nM neuromedin B to cause elevation of c-fos mRNA. Also, PD168368 in a dose-dependent manner inhibited the ability of 100 nM neuromedin B to cause phosphorylation of focal adhesion kinase. Using a [3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay, the order of antagonist potency to inhibit C6 proliferation was PD168368=PD176252>PD165929. Also, 1 microM PD168368 and PD176252 significantly inhibited colony number using a proliferation assay in vitro. PD168368 significantly inhibited C6 xenograft growth in nude mice in vivo. These results indicate that PD168368 is a C6 cell neuromedin B receptor antagonist, which inhibits proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104826     DOI: 10.1016/s0014-2999(00)00828-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats.

Authors:  Pin-Yen Su; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2011-03-18       Impact factor: 4.030

Review 2.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

3.  Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.

Authors:  Terry W Moody; Marc J Berna; Samuel Mantey; Veronica Sancho; Lisa Ridnour; David A Wink; Daniel Chan; Giuseppe Giaccone; Robert T Jensen
Journal:  Eur J Pharmacol       Date:  2010-04-11       Impact factor: 4.432

Review 4.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

5.  Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2010-10-13       Impact factor: 4.436

6.  Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.

Authors:  Mariane Jaeger; Carolina Nör; Caroline Brunetto de Farias; Ana Lucia Abujamra; Gilberto Schwartsmann; Algemir Lunardi Brunetto; Rafael Roesler
Journal:  Childs Nerv Syst       Date:  2013-10-03       Impact factor: 1.475

7.  Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors.

Authors:  Nieves González; Samuel A Mantey; Tapas K Pradhan; Veronica Sancho; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2009-05-20       Impact factor: 3.750

Review 8.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

Review 9.  Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.

Authors:  Terry W Moody; Lingaku Lee; Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-01       Impact factor: 5.555

10.  Hypoxia regulates the expression of the neuromedin B receptor through a mechanism dependent on hypoxia-inducible factor-1α.

Authors:  Hyun-Joo Park; Mi-Kyoung Kim; Su-Ryun Kim; Soo-Kyung Bae; Moon-Kyoung Bae
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.